Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity
- PMID: 19932216
- PMCID: PMC2999844
- DOI: 10.1016/j.vaccine.2009.11.001
Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity
Abstract
Live, attenuated Shigella vaccine candidates, such as Shigella sonnei strain WRSS1, Shigella flexneri 2a strain SC602, and Shigella dysenteriae 1 strain WRSd1, are attenuated principally by the loss of the VirG(IcsA) protein. These candidates have proven to be safe and immunogenic in volunteer trials and in one study, efficacious against shigellosis. One drawback of these candidate vaccines has been the reactogenic symptoms of fever and diarrhea experienced by the volunteers, that increased in a dose-dependent manner. New, second-generation virG(icsA)-based S. sonnei vaccine candidates, WRSs2 and WRSs3, are expected to be less reactogenic while retaining the ability to generate protective levels of immunogenicity seen with WRSS1. Besides the loss of VirG(IcsA), WRSs2 and WRSs3 also lack plasmid-encoded enterotoxin ShET2-1 and its paralog ShET2-2. WRSs3 further lacks MsbB2 that reduces the endotoxicity of the lipid A portion of the bacterial LPS. Studies in cell cultures and in gnotobiotic piglets demonstrate that WRSs2 and WRSs3 have the potential to cause less diarrhea due to loss of ShET2-1 and ShET2-2 as well as alleviate febrile symptoms by loss of MsbB2. In guinea pigs, WRSs2 and WRSs3 were as safe, immunogenic and efficacious as WRSS1.
Published by Elsevier Ltd.
Figures








Similar articles
-
Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.Vaccine. 2011 Aug 26;29(37):6371-8. doi: 10.1016/j.vaccine.2011.04.115. Epub 2011 May 17. Vaccine. 2011. PMID: 21596086
-
A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.Vaccine. 2018 Aug 6;36(32 Pt B):4880-4889. doi: 10.1016/j.vaccine.2018.06.063. Epub 2018 Jul 2. Vaccine. 2018. PMID: 30037478 Free PMC article. Clinical Trial.
-
Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.Infect Immun. 2002 Jun;70(6):2950-8. doi: 10.1128/IAI.70.6.2950-2958.2002. Infect Immun. 2002. PMID: 12010984 Free PMC article.
-
Shigellosis: the current status of vaccine development.Curr Opin Infect Dis. 2008 Jun;21(3):313-8. doi: 10.1097/QCO.0b013e3282f88b92. Curr Opin Infect Dis. 2008. PMID: 18448978 Review.
-
Inactivated and subunit vaccines to prevent shigellosis.Expert Rev Vaccines. 2009 Dec;8(12):1693-704. doi: 10.1586/erv.09.127. Expert Rev Vaccines. 2009. PMID: 19943764 Review.
Cited by
-
Vaccines against gastroenteritis, current progress and challenges.Gut Microbes. 2020 Nov 1;11(6):1486-1517. doi: 10.1080/19490976.2020.1770666. Epub 2020 Jun 18. Gut Microbes. 2020. PMID: 32552414 Free PMC article. Review.
-
Expression of Shigella flexneri ipaB Gene in Tobacco.Avicenna J Med Biotechnol. 2013 Apr;5(2):118-24. Avicenna J Med Biotechnol. 2013. PMID: 23799180 Free PMC article.
-
Development of Silica-Immobilized Vaccines for Improving Thermo-Tolerance and Shelf-Life.Kans J Med. 2020 Feb 26;13(Suppl 2):6-9. eCollection 2020. Kans J Med. 2020. PMID: 32256968 Free PMC article.
-
The role of oxyR and soxRS in oxidative stress survival in Shigella flexneri.Microbiol Res. 2012 Apr 20;167(4):238-45. doi: 10.1016/j.micres.2011.09.004. Epub 2011 Oct 19. Microbiol Res. 2012. PMID: 22015257 Free PMC article.
-
Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.Mass Spectrom Rev. 2015 May-Jun;34(3):268-422. doi: 10.1002/mas.21411. Epub 2014 May 26. Mass Spectrom Rev. 2015. PMID: 24863367 Free PMC article. Review.
References
-
- Niyogi SK. Increasing antimicrobial resistance—an emerging problem in the treatment of shigellosis. Clinical Microbiology and Infection. 2007 December;13(12):1141–3. - PubMed
-
- Morpeth SC, Thielman NM. Diarrhea in patients with AIDS. Current Treatment Options in Gastroenterology. 2006 February;9(1):23–37. - PubMed
-
- Iwalokun BA, Gbenle GO, Smith SI, Ogunledun A, Akinsinde KA, Omonigbehin EA. Epidemiology of shigellosis in Lagos, Nigeria: trends in antimicrobial resistance. Journal of Health, Population, and Nutrition. 2001 September;19(3):183–90. - PubMed
-
- Hien BT, Trang do T, Scheutz F, Cam PD, Molbak K, Dalsgaard A. Diarrhoeagenic Escherichia coli and other causes of childhood diarrhoea: a case-control study in children living in a wastewater-use area in Hanoi, Vietnam. Journal of Medical Microbiology. 2007 August;56(Pt 8):1086–96. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources